Physician adherence to ACR gout treatment guidelines: Perception versus practice

Postgraduate Medicine

Volumn 126, Issue 3, 2014, Pages 257-267

  Oderda, Gary M ^a   Shiozawa, Aki ^b   Walsh, Michael ^c   Hess, Kyle ^c   Brixner, Diana I ^a   Feehan, Michael ^c,d   Akhras, Kasem ^b  

^a UNIVERSITY OF UTAH   (United States)

^b Takeda Pharmaceuticals International Inc   (United States)

^c Modellers LLC   (United States)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

ACR gout guidelines; Gout; Physician adherence; Prophylactic treatment; Serum uric acid (sUA); Urate lowering therapy (ULT)

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; ANTIGOUT AGENT; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; URIC ACID;

ADULT; ARTICLE; CLINICAL PRACTICE; FEMALE; GENERAL PRACTITIONER; GOUT; HUMAN; HYPERURICEMIA; INTERVIEW; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERCEPTION; PROPHYLAXIS; PROTOCOL COMPLIANCE; URIC ACID BLOOD LEVEL; BLOOD; MEDICATION COMPLIANCE; PHYSICIAN; PRACTICE GUIDELINE; RHEUMATOLOGY; STATISTICS;

ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; GOUT; GOUT SUPPRESSANTS; GUIDELINE ADHERENCE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHYSICIANS; PHYSICIANS, PRIMARY CARE; PRACTICE GUIDELINES AS TOPIC; RHEUMATOLOGY; URIC ACID;

EID: 84906927539     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2014.05.2774     Document Type: Article

References (19)

1. Burns CM, Wortmann RL. Latest evidence on gout management: what the clinician needs to know. Ther Adv Chronic Dis. 2012;3(6):271-286.
2. Khanna D, Fitzgerald JD, Khanna PP, et al; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431-1446.
3. Centers for Disease Control and Prevention. Gout. http://www.cdc.gov/ arthritis/basics/gout.htm. Accessed May 28, 2013.
4. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. Oct. 2012;64(10):1447-61.
5. Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. Am J Manag Care. 2005;11(15 Suppl):S435-S442; quiz S465-468.
6. Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum. 2004;50(8):2400-2414.
7. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136-3141.
8. Terkeltaub RA. Clinical practice. Gout. N Engl J Med. 2003; 349(17):1647-1655.
9. Saag KG, Mikuls TR. Recent advances in the epidemiology of gout. Curr Rheumatol Rep. 2005;7(3):235-241.
10. Lawrence RC, Felson DT, Helmick CG, et al; National Arthritis Data Workshop. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26-35.
11. Agudelo C, Wise CM. Crystal-associated arthritis. Clin Geriatr Med. 1998;14(3):495-513.
12. Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004;31(8):1575-1581.
13. Brixner DI, Ho MJ. Clinical, humanistic, and economic outcomes of gout. Am J Manag Care. 2005;11(15 Suppl):S459-S464.
14. Perez-Ruiz F, Calabozo M, Pijoan J, Herrero-Beites A, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47(4):356-360.
15. Universal Survey, SurveyHealthcare. SurveyHealthcare Samples and Counts. http://www.surveyhealthcare.com/pdfs/CASRO-US.pdf. Accessed May 13, 2013.
16. Harrold LR, Mazor KM, Peterson D, Naz N, Firneno C, Yood RA. Patients' knowledge and beliefs concerning gout and its treatment: a population based study. BMC Musculoskelet Disord. 2012;13:180.
17. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63.
18. Maue SK, Segal R, Kimberlin CL, Lipowski EE. Predicting physician guideline compliance: an assessment of motivators and perceived barriers. Am J Manag Care. 2004;10(6):383-391.
19. Cabana M. Barriers to guideline adherence. Am J Manag Care. 1998;4(12 Suppl):S741-744; discussion S745-748.